Alghofili Mohammed, Alwhaibi Bader, Alassaf Abdullah Mohammed, Aldhasee Omar Wahaf, Aljerian Nawfal, Alsubaie Nawaf, Alhussien Ahmed, Alsaleh Saad
Emergency Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Ther Clin Risk Manag. 2024 Dec 28;20:955-962. doi: 10.2147/TCRM.S480084. eCollection 2024.
This study aimed to investigate the prevalence of recurrent and active epistaxis in adult patients presenting to the Emergency Department (ED) and explored the association of recurrent epistaxis with demographic characteristics, comorbidities and medications, and types of emergency interventions in adult epistaxis patients.
A retrospective cross-sectional study was conducted with data from Eds of two tertiary hospitals over three years, from January 2019 to January 2022. All adult patients aged ≥18 years with active epistaxis not resolved by pressure on the nose or head positioning were included. Demographic data, details of clinical presentation and clinical management were collected from the patient's electronic medical records.
Of 404 patients, 73 (18.1%) revisited the ED with recurrence of epistaxis within 28 days. There was a male predilection in the study, with an average age of 55.4 ± 18.03. Most patients had unilateral (n = 328, 81.2%) and anterior (n = 376, 93.1%) nasal bleeding. Heart failure as a comorbidity was associated with a significantly increased risk of recurrent epistaxis (p = 0.001). The most common treatments included expandable polyvinyl acetate packs (EPAP) (n = 198, 49%); topical xylometazoline (n = 108, 26.7%); and chemical cautery (n = 57, 14.1%). EPAP for controlling initial bleeding was significantly associated with ED revisits due to epistaxis (p = 0.033).
The prevalence of recurrent epistaxis mostly occurs in older-aged males. Congestive heart failure may be an under-recognised risk factor for recurrent epistaxis. In patients with a high risk of epistaxis recurrence, other treatment modalities should be sought aside from expandable polyvinyl acetate packs as they can increase the risk of rebleeding.
本研究旨在调查前往急诊科(ED)就诊的成年患者中复发性和活动性鼻出血的患病率,并探讨复发性鼻出血与人口统计学特征、合并症、药物以及成年鼻出血患者的急诊干预类型之间的关联。
进行了一项回顾性横断面研究,收集了2019年1月至2022年1月期间两家三级医院急诊科三年的数据。纳入所有年龄≥18岁、经捏鼻或头部位置调整后活动性鼻出血仍未缓解的成年患者。从患者的电子病历中收集人口统计学数据、临床表现细节和临床管理情况。
在404例患者中,73例(18.1%)在28天内因鼻出血复发再次前往急诊科就诊。该研究中男性居多,平均年龄为55.4±18.03岁。大多数患者为单侧鼻出血(n=328,81.2%)且为前部鼻出血(n=376,93.1%)。心力衰竭作为一种合并症与复发性鼻出血风险显著增加相关(p=0.001)。最常见的治疗方法包括可膨胀聚醋酸乙烯酯填塞物(EPAP)(n=198,49%);局部用赛洛唑啉(n=108,26.7%);以及化学烧灼(n=57,14.1%)。用于控制初始出血的EPAP与因鼻出血再次前往急诊科就诊显著相关(p=0.033)。
复发性鼻出血的患病率大多发生在老年男性中。充血性心力衰竭可能是复发性鼻出血一个未被充分认识的危险因素。对于鼻出血复发风险高的患者,除可膨胀聚醋酸乙烯酯填塞物外,应寻求其他治疗方式,因为它们会增加再次出血的风险。